


























Annexes

Table 1 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pK_i) to the data set (1 until 29 compounds).

<i>Compounds</i>	<i>Structures</i>	<i>- R</i>	<i>n</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
1			2	5	-	a)
2			3	6.69897	-	a)
3			4	8	-	a)
4			5	8.070581	-	a)
5			2	6	-	a)
6			3	7.886057	-	a)

<i>Compounds</i>	<i>Structures</i>	<i>- R</i>	<i>n</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
7			2	6.619789	-	a)
8			3	7.187087	-	a)
9			4	9	-	a)
10			-	7.958607	7.4085	a)
11			-	7.886057	-	a)
12			2	7.49485	-	a)
13			4	9.638272	-	a)

<i>Compounds</i>	<i>Structures</i>	<i>- R</i>	<i>n</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
14			2	7.267606	-	a)
15			3	7.886057	-	a)
16			4	9.721246	-	a)
17			5	8.69897	-	a)
18			-	8.004365	-	a)
19			-	8.69897	-	a)
20			-	9.221849	-	a)
21			-	7.259637	-	a)

<i>Compounds</i>	<i>Structures</i>	<i>- R</i>	<i>n</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
22			-	9.638272	-	a)
23		-	-	7.744727	-	a)
24			-	7.568636	-	a)
25		-	-	7.537602	-	a)
26			3	8.69897	-	a)
27			-	7.39794	-	a)
28			4	7.154902	5.4401	a)
29			-	10	-	a)

Table 2 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pK_i) to the data set (30 until 35 compounds).



































<i>Compounds</i>	<i>Structures</i>	<i>X</i>	<i>Ar</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
30		CH		6.9	7.82	b)
31		N		7.08	8.29	b)
32		N		7.41	7.98	b)
33		N		7.1	6.85	b)
34		CO-CO		7.06	5.81	b)
35		C-C ₆ H ₅		6.76	6.12	b)

Table 3 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pK_i) to the data set (36 until 54 compounds).

<i>Compounds</i>	<i>Structures</i>	<i>n</i>	<i>- R¹</i>	<i>- R</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
36		3	<i>m</i> -Cl		6.628932	7.80	c)
37		4	<i>m</i> -Cl		7.30103	5.74	c)
38		3	<i>o</i> -OCH ₃		7.267606	5.67	c)
39		4	<i>o</i> -OCH ₃		7.958607	5.84	c)
40		4	<i>m</i> -Cl		7.30103	7.17	c)
41		3	<i>o</i> -OCH ₃		7	6.34	c)
42		4	<i>o</i> -OCH ₃		7.443697	6.25	c)
43		3	<i>m</i> -Cl		6.381952	6.18	c)
44		4	<i>m</i> -Cl		6.39794	6.24	c)
45		3	<i>o</i> -OCH ₃		7.522879	6.52	c)
46		4	<i>o</i> -OCH ₃		7.366532	6.43	c)

<i>Compounds</i>	<i>Structures</i>	<i>n</i>	<i>- R¹</i>	<i>- R</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
47		3	<i>m</i> -Cl		6.686133	6.57	c)
48		-	-	2-Cl	6.474955	5.22	d)
49		-	-	2-F	6.501689	5.00	d)
50		-	-	4-Cl	7.279841	6.00	d)
51		-	-	4-F	5.966979	5.35	d)
52		-	-	4-Ph	6.392545	6.77	d)
53		-	-	4-CF ₃	6.417937	6.21	d)
54		-	-	4-SMe	6.054531	5.87	d)

Table 4 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pK_i) to the data set (55 until 59 compounds).

Compounds	Structures	n	X	- R	pK _i		Ref.
					5-HT _{1A}	5-HT _{2A}	
55		2	H	3'-Cl	7.638272	6.63	e)
56		2	Br	2'-OCH ₃	7.207608	7.07	e)
57		3	Br	H	7.958607	6.53	e)
58		3	Br	3'-Cl	7.309804	7.07	e)
59		3	Br	2'-OCH ₃	7.443697	6.06	e)







Table 5 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pK_i) to the data set (60 until 76 compounds).







<i>Compounds</i>	<i>Structure</i>	<i>Ar</i>	<i>[Linker]</i>	<i>-R</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
60				2,3-diCl	6.510042	7.03	f)
61				2,3-diCl	7.036212	7.33	f)
62				2-OCH ₃	7.66354	7.12	f)
63				2-OCH ₃	7.143876	7.18	f)
64				2,3-diCl	7.464706	7.37	f)
65				2,3-diCl	5.742321	6.26	f)
66				2-OCH ₃	7.441291	6.16	f)
67				2,3-diCl	6.931814	7.05	f)
68				2,3-diCl	7.821023	7.81	f)
69				2,3-diCl	5.69037	6.17	f)
70				2,3-diCl	7.229148	7.33	f)
71				2,3-diCl	6.007889	6.05	f)
72				2,3-diCl	7.630784	7.64	f)
73				2,3-diCl	6.02641	6.48	f)
74				2-OCH ₃	7.468521	6.81	f)
75				2-OCH ₃	8.173277	6.64	f)

<i>Compounds</i>	<i>Structure</i>	<i>Ar</i>	<i>[Linker]</i>	<i>-R</i>	pK_i 5-HT _{1A}	pK_i 5-HT _{2A}	<i>Ref.</i>
76				2,3-diCl	7.527244	7.81	f)








Table 6 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pKi) to the data set (77 until 114 compounds).

<i>Compounds</i>	<i>Structure</i>	pK_i 5-HT _{1A}	pK_i 5-HT _{2A}	<i>Ref.</i>
77		6.420216	-	r)
78		6.641998	8.00	r) e h)
79		6.922652	6.90	r)
80		7.20	7.80	i) e j)
81		5.770318	6.48	r)
82		7.713971	8.50	r) e k)

<i>Compounds</i>	<i>Structure</i>	<i>pK_i</i> <i>5-HT1A</i>	<i>pK_i</i> <i>5-HT2A</i>	<i>Ref.</i>
83		7.026626	6.69	r)
84		7.801125	6.86	r)
85		8.70	-	q) e l)
86		9.30	-	q) e l)
87		8.70	5.30	r); l) e m)
88		9.70	-	l) e m)

<i>Compounds</i>	<i>Structure</i>	<i>pK_i</i>		<i>Ref.</i>
		<i>5-HT_{1A}</i>	<i>5-HT_{2A}</i>	
89		10.50	-	l) e m)
90		9.20	-	m)
91		5.229148	7.82	r)
92		8.113509	8.18	r)
93		8.60	-	n)
94		6.884822	-	r)

<i>Compounds</i>	<i>Structure</i>	<i>pK_i</i> <i>5-HT1A</i>	<i>pK_i</i> <i>5-HT2A</i>	<i>Ref.</i>
95		8.20	7.70	o)
96		7.278189	6.49	p)
97		8.065502	5.90	p)
98		6.554396	6.58	p)
99		8.414539	4.91	p)
100		7.619789	5.47	p)

<i>Compounds</i>	<i>Structure</i>	<i>pK_i</i> <i>5-HT1A</i>	<i>pK_i</i> <i>5-HT2A</i>	<i>Ref.</i>
101		6.89279	7.11	p)
102		6.737549	6.55	p)
103		7.017729	6.52	p)
104		7.779892	6.15	p)
105		6.306273	5.40	p)
106		5.505289	5.40	p)
107		7.101275	5.47	p)








<i>Compounds</i>	<i>Structure</i>	<i>pK_i</i> <i>5-HT1A</i>	<i>pK_i</i> <i>5-HT2A</i>	<i>Ref.</i>
108		6.774691	5.50	p)
109		7.221849	-	p)
110		6.777284	5.32	p)
111		7.72	-	r)
112		6.00	-	r)
113		5.610834	-	r)
114		5.69897	-	r)

Table 7 - The 5-HT_{1A} and 5-HT_{2A} receptors binding affinities (pK_i) to the data set (115 until 129 compounds).

<i>Compounds</i>	<i>Structure</i>	<i>Ar</i>	<i>-R</i>	<i>pK_i</i> <i>5-HT_{1A}</i>	<i>pK_i</i> <i>5-HT_{2A}</i>	<i>Ref.</i>
115			CH ₃	-	5.63	g)
116			OCH ₃	-	6.86	g)
117			CH ₃	-	6.03	g)
118			OCH ₃	-	5.71	g)
119			CH ₃	-	6.76	g)
120			OCH ₃	-	5.51	g)
121			CH ₃	-	5.97	g)
122			OCH ₃	-	6.27	g)
123		-	-	-	5.40	k)

<i>Compounds</i>	<i>Structure</i>	<i>Ar</i>	<i>-R</i>	<i>pK_i</i> 5-HT _{1A}	<i>pK_i</i> 5-HT _{2A}	<i>Ref.</i>
124		-	-	-	5.17	r)
125		-	-	-	8.12	r)
126		-	-	-	4.48	r)
127		-	-	-	6.83	r)
128		-	-	-	9.51	r)
129		-	-	-	6.90	r)

Legend:

- a) López-Rodríguez *et al.*, 2002;
b) Tomić *et al.*, 2004;
c) Bojarski *et al.*, 2002;
d) Lu *et al.*, 2005;
e) Jurczyk *et al.*, 2004;
f) Grundt *et al.*, 2007;
g) González-Gómez *et al.*, 2003;
h) Sanchez *et al.*, 1999;
i) Price *et al.*, 1999;

- j) Gaster *et al.*, 1998;
k) Knight *et al.*, 2004;
l) Newman-Tancredi *et al.*, 1998;
m) Newman-Tancredi *et al.*, 1998a;
n) Jorand-Lebrun *et al.*, 1997;
o) Shapiro *et al.*, 2003;
p) www.bindingdb.org;
q) www.iuphar-db.org;
r) Protein ki Database (2008)
<http://kidb.cwru.edu/pdsp.php>.

References

- a. López-Rodríguez ML, Ayala D, Benhamú B, Morcillo MJ, Viso A. Arylpiperazine derivatives acting at 5-HT_{1A} receptors. *Curr Med I Chem* 2002; 9: 443-469.
- b. Tomić M, Kundaković M, Butorović B, Janać B, Andrić D, Roglić G, Ignjatović D, Kostić-Rajacić S. Pharmacological evaluation of selected

- arylpiperazines with atypical antipsychotic potential. *Bioorganic & Medicinal Chemistry Letters* 2004; 14: 4263–4266.
- c. Bojarski AJ, Kowalski P, Kowalska T, Duszynska B, Charakchieva-Minol S, Tatarczynska E, Klodzinska A, Chojnacka-Wójcik E. Synthesis and Pharmacological Evaluation of New Arylpiperazines. 3-{4-[4-(3-chlorophenyl)-1-piperazinyl]butyl}-quinazolidin-4-one — A Dual Serotonin 5-HT_{1A}/5-HT_{2A} Receptor Ligand with an Anxiolytic-Like Activity. *Bioorganic & Medicinal Chemistry* 2002; 10: 3817–3827.
- d. Lu SY, Hong J, Musachio JL, Chin FT, Vermeulen ES, Wikström HV, Pike VW. Alternative methods for labeling the 5-HT_{1A} receptor agonist, 1-[2-(4-fluorobenzoylamino)ethyl]-4-(7-methoxynaphthyl)piperazine (S14506), with carbon-11 or fluorine-18. *J Label Compd Radiopharm* 2005; 48: 971–981.
- e. Jurczyk S, Kołaczkowski M, Maryniak E, Zajdel P, Pawłowski M, Tatarczynska E, Klodzinska A, Chojnacka-Wójcik E, Bojarski A, Charakchieva-Minol S, Duszynska B, Nowak G, Maciaü D. New Arylpiperazine 5-HT_{1A} Receptor Ligands Containing the Pyrimido[2,1-f]purine Fragment: Synthesis, in Vitro, and in Vivo Pharmacological Evaluation. *J Med Chem* 2004; 47: 2659-2666.
- f. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi J, Jenkins BG, Luedtke RR, Newman AH. Heterocyclic Analogues of N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with Functionalized Linking Chains as Novel Dopamine D₃ Receptor Ligands: Potential Substance Abuse Therapeutic Agents. *J Med Chem* 2007; 50: 4135-4146.
- g. González-Gómez JC, Santana L, Uriarte E, Brea J, Villazón M, Loza MI, De Luca M, Rivas ME, Montenegro GY, Fontenla JA. New arylpiperazine derivatives with high affinity for alpha_{1A}, D₂ and 5-HT_{2A} receptors. *Bioorg Med Chem Lett* 2003; 13(2):175-8.
- h. Sanchez C, Hyttel J. Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding. *Celular and Molecular Neurobiology* 1999; 19 (4): 467-89.
- i. Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Gothert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN. SB-216641 and BRL-15572 compounds to pharmacologically discriminate h5-HT_{1B} and h5-HT_{1D} receptors. *Naunyn Schmiedebergs Arch Pharmacol* 1999; 356: 312 - 320.
- j. Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD. The selective 5-HT_{1B} receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine]

- (SB224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. *J Med Chem* 1998; 41: 1218 - 1235.
- k. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. *Naunyn Schmiedebergs Arch Pharmacol* 2004; 370: 114 - 123.
 - l. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrielle L, Audinot V, Millan MJ. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [³⁵S]GTPgammaS binding study. *Eur J Pharmacol* 1998; 355: 245 - 256.
 - m. Newman-Tancredi A, Verrielle L, Chaput C, Millan MJ. Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [³H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. *Naunyn Schmiedebergs Arch Pharmacol* 1998a; 357: 205 - 217.
 - n. Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S. 5-HT1B receptor antagonist properties of novel arylpiperazine derivatives of 1-naphthylpiperazine. *J Med Chem* 1997; 40: 3974 - 3978.
 - o. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. *Neuropsychopharmacology* 2003; 28: 1400 - 1411.
 - p. www.bindingdb.org
 - q. www.iuphar-db.org
 - r. Protein ki Database (2008) <http://kidb.cwru.edu/pdsp.php>